<DOC>
	<DOCNO>NCT01328041</DOCNO>
	<brief_summary>The purpose trial assess antiviral activity safety dolutegravir ( DTG ) contain regimen HIV-1 infect , antiretroviral therapy ( ART ) -experienced adults current historical failure integrase inhibitor ( INI ) contain regimen . The study ass DTG 50mg twice daily administer initially current fail ART regimen optimise background ART regimen ( OBR ) Day 7 . The first analysis conduct last subject enrol complete 24 week . Subjects may remain study Week 24 .</brief_summary>
	<brief_title>A Study Assess Dolutegravir HIV-infected Subjects With Treatment Failure Integrase Inhibitor Containing Regimen .</brief_title>
	<detailed_description>ING112574 Phase 3 , multicentre , open-label , single arm study assess antiviral activity safety DTG contain regimen HIV-1 infect ART-experienced adult historical current evidence resistance RAL ELV . Initially , minimum 100 subject enrol receive DTG 50mg twice daily current fail regimen 7 day OBR Day 8 . Subjects must also document genotypic and/or phenotypic resistance least one compound two approve class ART must also able include least one fully active drug OBR start Day 8 . The first data cut take place ( approximate ) 100th subject enrol completes Week 24 visit . Enrollment continue 50 100 subject recruit . All subject successfully complete 24 week treatment continue access DTG locally available long continue derive clinical benefit . ViiV Healthcare sponsor study .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<criteria>Screening plasma HIV1 RNA ≥500 copies/mL ARTexperienced , INIexperienced , DTG naïve Experienced virological failure raltegravir ( RAL ) elvitegravir ( ELV ) regimen The subject 's HIV1 show resistance RAL ELV Screening prior time point virological failure RAL ELV Documented resistance least one drug three approve class ART Be able receive least one fully active drug part OBR Day 8 Women capable become pregnant must use appropriate contraception study ( define protocol ) Willing able understand provide sign dated write informed consent prior Screening . Women pregnant breast feed An active AIDSdefining condition Screening ( except cutaneous Kaposi 's sarcoma require systemic therapy CD4+ &lt; 200c/mm3 ) Moderate severe hepatic impairment define ChildPugh classification Anticipated need HCV therapy first 24 week study Recent history upper low gastrointestinal bleed , exception anal rectal bleeding Allergy intolerance study drug component drug class Malignancy within past 6 month Treatment HIV1 therapeutic vaccine within 90 day Screening Treatment radiation therapy , cytotoxic chemotherapeutic agent immunomodulator within 28 day Screening Treatment agent , license ART , document activity HIV1 vitro within 28 day first dose investigational product Treatment etravirine , efavirenz , nevirapine within 14 day Day 1 ( etravirine may use coadministered lopinivir/ritonavir darunavir/ritonavir ) Treatment tipranivir/ritonavir , fosamprenavir , fosamprenavir/ritonavir within 28 day prior Screening Verified Grade 4 laboratory abnormality Screening ALT &gt; 5 time upper limit normal ( ULN ) Screening ALT ≥ 3X ULN bilirubin &gt; 1.5 X ULN ( 35 % direct bilirubin ) Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>GSK1349572</keyword>
	<keyword>resistance raltegravir elvitegravir</keyword>
	<keyword>Integrase inhibitor</keyword>
	<keyword>ART-experienced</keyword>
	<keyword>dolutegravir</keyword>
</DOC>